00:52 , Aug 17, 2018 |  BC Innovations  |  Targets & Mechanisms

RNA party

A study in Cell uncovered a brain regulatory network involving a circular RNA, a long non-coding RNA and two microRNAs, and could provide some much needed insights in a field where finding links to disease...
16:22 , Jul 11, 2018 |  BC Innovations  |  Translation in Brief

The RNA Renaissance continues

Two papers from Matthew Disney’s lab at The Scripps Research Institute herald a pair of RNA-related discoveries: a method for engineering small molecules that target and cleave oncogenic microRNAs, and a platform that identified RNA-targeting...
21:28 , May 24, 2018 |  BC Extra  |  Preclinical News

miRNA-targeted circular single-stranded DNA to treat cancer

A Nankai University-based team developed a small circular single-stranded DNA molecule that inhibits cancer growth in cells and mice by sequestering microRNAs (miRNAs) that silence tumor suppressor genes. Preclinical deals in nucleic acid modalities over the...
16:20 , May 23, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens; biomarkers

TECHNOLOGY: Cell-free assays; gene profiling A method for profiling miRNAs in extracellular vesicles could be used to identify diagnostic markers for pancreatic and other cancers. The method involves linking magnetic anti-biotin microbeads to biotinylated antibodies that...
02:06 , May 11, 2018 |  BC Innovations  |  Finance

Amplifying oligos

The last five years have seen a steady stream of preclinical deals for antisense, siRNA and mRNA therapies that suggests pharmas are taking the modalities seriously as alternatives to traditional small molecules and antibodies. But...
16:29 , May 4, 2018 |  BC Week In Review  |  Clinical News

uniQure reports preclinical data for Huntington's disease candidate

uniQure N.V. (NASDAQ:QURE) reported preclinical data showing that AMT-130 decreased mutant huntingtin (HTT) protein in animal models of Huntington's disease. Data were presented at the American Academy of Neurology meeting in Los Angeles. In a pig...
16:17 , May 4, 2018 |  BC Week In Review  |  Financial News

uniQure raises $128.5M follow-on

Gene therapy company uniQure N.V. (NASDAQ:QURE) raised $128.5 million on May 3 in a follow-on through the sale of 4.5 million shares at $28.50. Leerink Partners, Evercore ISI, Wells Fargo Securities, Chardan, H.C. Wainwright &...
17:21 , May 3, 2018 |  BC Extra  |  Financial News

uniQure raises $128.5M follow-on

Gene therapy company uniQure N.V. (NASDAQ:QURE) raised $128.5 million in a follow-on Thursday through the sale of 4.5 million shares at $28.50. Leerink Partners, Evercore ISI, Wells Fargo Securities, Chardan, H.C. Wainwright & Co. and...
17:21 , Apr 13, 2018 |  BC Week In Review  |  Company News

Quadrant licenses epigenetic diagnostics from SUNY, Penn State

Quadrant Biosciences Inc. (Syracuse, N.Y.) licensed three epigenetic biomarkers from the State University of New York Upstate Medical University and Pennsylvania State University for autism spectrum disorder (ASD), Parkinson's disease and traumatic brain injury (TBI). The...
03:45 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...